Arcus Biosciences, Inc.
https://www.arcusbio.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Arcus Biosciences, Inc.
Roche’s Data Leak Reawakens Hopes For TIGIT Lung Cancer Drug
An “inadvertent disclosure” of data has done Roche’s share price no harm, but analysts are still unsure that its TIGIT immunotherapy can prove a threat to Merck’s all-conquering Keytruda.
Merck’s Welireg Could Expand Into Broader Kidney Cancer Indication With Phase III Data
The drug maker announced Phase III results for the HIF-2α inhibitor in renal cell carcinoma patients with disease progression following PD-1/PD-L1 and anti-VEGF therapy.
Gilead’s Trodelvy May Have Safety Edge Due To Lack Of Concerning Lung Toxicity
Executives said there had been no cases of interstitial lung disease, while ILD – including fatal events – has become a potential problem for AstraZeneca/Daiichi Sankyo’s dato-DXd.
Novartis Says No To TIGIT, Backs Out Of BeiGene Deal
Novartis declined to option BeiGene’s TIGIT inhibitor, ociperlimab. BeiGene will continue a Phase III study combining it with PD-1 inhibitor tislelizumab while dropping another Phase III.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice